ArticleJVS-vascular science2021
Inhibition of angiotensin-induced aortic aneurysm by metformin in apolipoprotein E-deficient mice.
Article in JVS-vascular science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Mitochondrial Functional Capacity Is Impaired in Angiotensin II-Infused Mice and Not Recovered by Metformin.Biomedicines · 2026Article
- Metformin and beyond: glucose-lowering therapy as a potential modulator of abdominal aortic aneurysm growth and stability- systematic review with narrative synthesis.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Histomorphologic characteristics of abdominal aortic aneurysm samples are similar in abdominal-only vs thoracoabdominal involvement.JVS-vascular science · 2026Article
- Metformin does not attenuate angiotensin II-induced aortic aneurysms in low-density lipoprotein receptor deficient mice.Scientific reports · 2025Article
- Perivascular adipose tissue inflammation in abdominal aortic aneurysm: An underrecognized contributor.Journal of biomedical research · 2025Article
- Therapeutic Strategies for Abdominal Aortic Aneurysm: A Comprehensive Systematic Review.Journal of cardiovascular development and disease · 2025Review
- Single-cell spatial transcriptomics unravels the cellular landscape of abdominal aortic aneurysm.JCI insight · 2025Article
- Evaluation of Metabolism-Associated Proteins in Abdominal Aortic Aneurysm.Journal of vascular research · 2025Article
- Melanocortin-4 receptor in macrophages attenuated angiotensin II-induced abdominal aortic aneurysm in mice.Scientific reports · 2023Article
- Mechanisms and efficacy of metformin-mediated suppression of established experimental abdominal aortic aneurysms.JVS-vascular science · 2023Article
- Metformin ameliorates established abdominal aortic aneurysms induced by elastase in mice.JVS-vascular science · 2023Article
- Metformin suppresses vascular smooth muscle cell senescence by promoting autophagic flux.Journal of advanced research · 2022Article
- Development of pharmacotherapies for abdominal aortic aneurysms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Association of IL-10 and CRP with Pulse Wave Velocity in Patients with Abdominal Aortic Aneurysm.Journal of clinical medicine · 2022Article
- Double-edged sword of diabetes mellitus for abdominal aortic aneurysm.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMetformin is associated with a reduced incidence and growth of abdominal aortic aneurysms (AAAs). The aim of the present study was to investigate the inhibitory effects of metformin on AAA development and possible underlying mechanisms in experimentally induced AAAs in mice, along with the possible synergistic effects of metformin and imatinib.
methodsAngiotensin II was used to induce AAAs in apolipoprotein E knockout (
resultsMetformin (n = 11) suppressed the formation and progression of AAAs by 50% compared with the vehicle controls (n = 12), with no further effects from imatinib (n = 7). Metformin reduced total cholesterol and mRNA expression of
conclusionMetformin inhibited aneurysm formation and progression and normalized vascular function in CLINICAL RELEVANCE: Retrospective studies of the effects of metformin in patients with aneurysm have so far only been performed of those with type 2 diabetes. The present study shows that metformin has effects on nondiabetic mice and revealed the mechanistic effects mediated by the drug that could also be important to study as outcomes in humans. Future clinical trials using metformin are warranted in patients without diabetes with abdominal aortic aneurysms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.